Brief: Neurocrine Biosciences And Voyager Therapeutics Collaborates For Neurological Disease Treatments

Voyager Therapeutics

09/01/2023 13:10

Jan 9 (Reuters) - Neurocrine Biosciences Inc  NBIX.O :
    * NEUROCRINE BIOSCIENCES AND VOYAGER THERAPEUTICS ENTER
STRATEGIC
COLLABORATION FOR DEVELOPMENT AND COMMERCIALIZATION OF VOYAGER’S
GBA1 PROGRAM AND OTHER NEXT-GENERATION GENE THERAPIES FOR
NEUROLOGICAL DISEASES
    * VOYAGER THERAPEUTICS INC - VOYAGER TO RECEIVE UP-FRONT
CONSIDERATION OF $175 MILLION INCLUDING A $39 MILLION EQUITY
INVESTMENT,
    * VOYAGER THERAPEUTICS INC - NEUROCRINE TO RECEIVE WORLDWIDE
RIGHTS TO VOYAGER'S GBA1 GENE THERAPY PROGRAM FOR PARKINSON'S
DISEASE
    * VOYAGER - NEUROCRINE TO RECEIVE WORLDWIDE RIGHTS TO
VOYAGER'S
OTHER GBA1-MEDIATED DISEASES & THREE GENE THERAPY PROGRAMS
DIRECTED TO RARE CNS TARGETS
    * VOYAGER - NEUROCRINE AGREED TO PAY APPROXIMATELY $136
MILLION IN
CASH AND TO PURCHASE APPROXIMATELY $39 MILLION OF NEWLY ISSUED
EQUITY IN VOYAGER
    * VOYAGER - REGARDING GBA1 GENE THERAPY PROGRAM, NEUROCRINE
BIOSCIENCES HAS AGREED TO FUND DEVELOPMENT THROUGH COMPLETION OF
A FIRST PHASE 1 TRIAL.
    * VOYAGER - FOLLOWING DATA READOUT , VOYAGER HAS RIGHT, BUT
NOT
OBLIGATION, TO ELECT TO CO-DEVELOP & CO-COMMERCIALIZE GBA1
PROGRAM WITH NEUROCRINE IN U.S
    * VOYAGER - IF VOYAGER DECLINES ITS OPTION FOR COST, PROFIT
SHARING ON GBA1, CO WILL BE ELIGIBLE FOR UP TO $985 MILLION IN
PAYMENTS

Source text for Eikon:  ID:nGNX8TY3G9 
Further company coverage:  NBIX.O 
 ((Reuters.Briefs@thomsonreuters.com;))